

EDSS: Change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Confirmed Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Change from Baseline to Week 156			
n	162	141	
Mean	0.38	0.36	0.7122
SD	0.631	0.703	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6).

EDSS: Change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Non Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Change from Baseline to Week 156			
n	98	134	
Mean	-0.33	-0.25	0.3861
SD	0.718	0.775	

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6).